North China Pharmaceutical Co Ltd (600812) - Net Assets

Latest as of March 2026: CN¥6.93 Billion CNY ≈ $1.01 Billion USD

Based on the latest financial reports, North China Pharmaceutical Co Ltd (600812) has net assets worth CN¥6.93 Billion CNY (≈ $1.01 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥21.45 Billion ≈ $3.14 Billion USD) and total liabilities (CN¥14.52 Billion ≈ $2.12 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore North China Pharmaceutical Co Ltd (600812) total assets for the complete picture of this company's asset base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥6.93 Billion
% of Total Assets	32.32%
Annual Growth Rate	6.07%
5-Year Change	-1.88%
10-Year Change	30.12%
Growth Volatility	41.14

North China Pharmaceutical Co Ltd - Net Assets Trend (1993–2025)

This chart illustrates how North China Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Check North China Pharmaceutical Co Ltd tangible equity quality to evaluate the tangible quality of the company's equity base.

Annual Net Assets for North China Pharmaceutical Co Ltd (1993–2025)

The table below shows the annual net assets of North China Pharmaceutical Co Ltd from 1993 to 2025. For live valuation and market cap data, see North China Pharmaceutical Co Ltd market cap and net worth.

Year	Net Assets	Change
2025-12-31	CN¥6.88 Billion ≈ $1.01 Billion	+3.15%
2024-12-31	CN¥6.67 Billion ≈ $976.71 Million	+6.45%
2023-12-31	CN¥6.27 Billion ≈ $917.56 Million	+0.67%
2022-12-31	CN¥6.23 Billion ≈ $911.41 Million	-11.24%
2021-12-31	CN¥7.02 Billion ≈ $1.03 Billion	-0.54%
2020-12-31	CN¥7.06 Billion ≈ $1.03 Billion	+25.45%
2019-12-31	CN¥5.62 Billion ≈ $822.98 Million	+2.03%
2018-12-31	CN¥5.51 Billion ≈ $806.58 Million	+4.38%
2017-12-31	CN¥5.28 Billion ≈ $772.71 Million	-0.20%
2016-12-31	CN¥5.29 Billion ≈ $774.28 Million	+0.41%
2015-12-31	CN¥5.27 Billion ≈ $771.13 Million	+0.45%
2014-12-31	CN¥5.25 Billion ≈ $767.70 Million	+26.54%
2013-12-31	CN¥4.15 Billion ≈ $606.67 Million	-0.77%
2012-12-31	CN¥4.18 Billion ≈ $611.39 Million	+217.99%
2011-12-31	CN¥1.31 Billion ≈ $192.27 Million	+11.19%
2010-12-31	CN¥1.18 Billion ≈ $172.92 Million	+32.64%
2009-12-31	CN¥890.92 Million ≈ $130.37 Million	-46.66%
2008-12-31	CN¥1.67 Billion ≈ $244.43 Million	+14.74%
2007-12-31	CN¥1.46 Billion ≈ $213.02 Million	+4.72%
2006-12-31	CN¥1.39 Billion ≈ $203.42 Million	-4.66%
2005-12-31	CN¥1.46 Billion ≈ $213.37 Million	-15.22%
2004-12-31	CN¥1.72 Billion ≈ $251.66 Million	-37.58%
2003-12-31	CN¥2.76 Billion ≈ $403.19 Million	+3.28%
2002-12-31	CN¥2.67 Billion ≈ $390.38 Million	-1.23%
2001-12-31	CN¥2.70 Billion ≈ $395.23 Million	-0.10%
2000-12-31	CN¥2.70 Billion ≈ $395.61 Million	+1.59%
1999-12-31	CN¥2.66 Billion ≈ $389.44 Million	+39.21%
1998-12-31	CN¥1.91 Billion ≈ $279.75 Million	-0.88%
1997-12-31	CN¥1.93 Billion ≈ $282.24 Million	+38.43%
1996-12-31	CN¥1.39 Billion ≈ $203.88 Million	+18.88%
1995-12-31	CN¥1.17 Billion ≈ $171.51 Million	+0.17%
1994-12-31	CN¥1.17 Billion ≈ $171.22 Million	+11.95%
1993-12-31	CN¥1.05 Billion ≈ $152.95 Million	--

Equity Component Analysis

This analysis shows how different components contribute to North China Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 396.9% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Other Components	CN¥5.92 Billion	107.34%
Total Equity	CN¥5.51 Billion	100.00%

North China Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of North China Pharmaceutical Co Ltd ranked by their market capitalization.

Company	Market Cap
Shanghai QiFan Cable Co Ltd SHG:605222	$1.20 Billion
Direcional Engenharia S.A. SA:DIRR3	$1.20 Billion
Borr Drilling Ltd NYSE:BORR	$1.20 Billion
FuelCell Energy Inc NASDAQ:FCEL	$1.20 Billion
Deluxe Corporation NYSE:DLX	$1.19 Billion
Wuxi Xinhongye Wire & Cable Co. Ltd. A SHE:301310	$1.19 Billion
Hitevision Co Ltd SHE:002955	$1.19 Billion
ARB Corporation Ltd AU:ARB	$1.19 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in North China Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 5,389,402,984 to 5,514,831,273, a change of 125,428,289 (2.3%).
Net income of 183,056,161 contributed positively to equity growth.
Dividend payments of 412,842,068 reduced retained earnings.
Other comprehensive income decreased equity by 364,336,871.
Other factors increased equity by 719,551,067.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CN¥183.06 Million	+3.32%
Dividends Paid	CN¥412.84 Million	-7.49%
Other Comprehensive Income	CN¥-364.34 Million	-6.61%
Other Changes	CN¥719.55 Million	+13.05%
Total Change	CN¥-	2.33%

Book Value vs Market Value Analysis

This analysis compares North China Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.48x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 4.70x to 1.48x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
1993-12-31	CN¥1.01	CN¥4.76	x
1994-12-31	CN¥1.13	CN¥4.76	x
1995-12-31	CN¥1.13	CN¥4.76	x
1996-12-31	CN¥1.33	CN¥4.76	x
1997-12-31	CN¥1.80	CN¥4.76	x
1998-12-31	CN¥1.78	CN¥4.76	x
1999-12-31	CN¥2.42	CN¥4.76	x
2000-12-31	CN¥2.45	CN¥4.76	x
2001-12-31	CN¥2.37	CN¥4.76	x
2002-12-31	CN¥1.43	CN¥4.76	x
2003-12-31	CN¥1.46	CN¥4.76	x
2004-12-31	CN¥0.89	CN¥4.76	x
2005-12-31	CN¥0.73	CN¥4.76	x
2006-12-31	CN¥1.14	CN¥4.76	x
2007-12-31	CN¥1.21	CN¥4.76	x
2008-12-31	CN¥1.42	CN¥4.76	x
2009-12-31	CN¥0.78	CN¥4.76	x
2010-12-31	CN¥0.99	CN¥4.76	x
2011-12-31	CN¥1.12	CN¥4.76	x
2012-12-31	CN¥3.66	CN¥4.76	x
2013-12-31	CN¥2.96	CN¥4.76	x
2014-12-31	CN¥3.38	CN¥4.76	x
2015-12-31	CN¥3.28	CN¥4.76	x
2016-12-31	CN¥3.22	CN¥4.76	x
2017-12-31	CN¥3.39	CN¥4.76	x
2018-12-31	CN¥3.32	CN¥4.76	x
2019-12-31	CN¥3.41	CN¥4.76	x
2020-12-31	CN¥3.76	CN¥4.76	x
2021-12-31	CN¥3.57	CN¥4.76	x
2022-12-31	CN¥3.09	CN¥4.76	x
2023-12-31	CN¥3.26	CN¥4.76	x
2024-12-31	CN¥3.14	CN¥4.76	x
2025-12-31	CN¥3.21	CN¥4.76	x

Capital Efficiency Dashboard

This dashboard shows how efficiently North China Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 3.32%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 1.98%
• Asset Turnover: 0.43x
• Equity Multiplier: 3.88x
Recent ROE (3.32%) is below the historical average (3.51%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
1993	15.34%	17.74%	0.62x	1.40x	CN¥55.82 Million
1994	17.74%	18.06%	0.62x	1.58x	CN¥90.54 Million
1995	20.46%	16.98%	0.64x	1.89x	CN¥121.74 Million
1996	15.03%	13.13%	0.56x	2.03x	CN¥68.90 Million
1997	10.34%	13.14%	0.42x	1.88x	CN¥6.24 Million
1998	5.44%	7.51%	0.34x	2.13x	CN¥-83.73 Million
1999	4.15%	6.36%	0.29x	2.23x	CN¥-146.24 Million
2000	3.82%	4.10%	0.40x	2.36x	CN¥-156.12 Million
2001	4.55%	3.91%	0.39x	3.01x	CN¥-133.04 Million
2002	5.34%	4.36%	0.43x	2.84x	CN¥-114.10 Million
2003	8.65%	6.04%	0.49x	2.90x	CN¥-33.85 Million
2004	3.87%	1.42%	0.54x	5.01x	CN¥-93.14 Million
2005	-14.96%	-4.72%	0.57x	5.58x	CN¥-313.10 Million
2006	-1.02%	-0.30%	0.57x	5.95x	CN¥-129.79 Million
2007	4.86%	1.43%	0.64x	5.35x	CN¥-64.11 Million
2008	19.10%	5.69%	0.70x	4.81x	CN¥133.03 Million
2009	-46.16%	-7.44%	0.68x	9.16x	CN¥-447.76 Million
2010	23.75%	2.35%	1.13x	8.96x	CN¥139.99 Million
2011	10.90%	1.02%	1.09x	9.84x	CN¥10.26 Million
2012	0.44%	0.16%	0.82x	3.33x	CN¥-389.42 Million
2013	0.34%	0.11%	0.85x	3.60x	CN¥-390.26 Million
2014	0.74%	0.41%	0.60x	2.99x	CN¥-481.84 Million
2015	1.19%	0.80%	0.49x	3.02x	CN¥-465.99 Million
2016	1.02%	0.67%	0.49x	3.10x	CN¥-476.86 Million
2017	0.35%	0.24%	0.45x	3.23x	CN¥-511.88 Million
2018	2.77%	1.64%	0.51x	3.29x	CN¥-393.60 Million
2019	3.10%	1.50%	0.62x	3.33x	CN¥-383.86 Million
2020	1.59%	0.85%	0.48x	3.91x	CN¥-515.11 Million
2021	0.31%	0.18%	0.42x	4.10x	CN¥-589.82 Million
2022	-13.00%	-6.56%	0.49x	4.00x	CN¥-1.22 Billion
2023	0.09%	0.05%	0.48x	3.94x	CN¥-526.64 Million
2024	2.36%	1.29%	0.46x	3.98x	CN¥-411.95 Million
2025	3.32%	1.98%	0.43x	3.88x	CN¥-368.43 Million

Industry Comparison

This section compares North China Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $2,133,881,544
Average return on equity (ROE) among peers: 2.68%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
North China Pharmaceutical Co Ltd (600812)	CN¥6.93 Billion	15.34%	2.09x	$1.20 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078)	$868.76 Million	4.89%	3.05x	$639.13 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153)	$775.01 Million	2.45%	0.87x	$378.07 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423)	$10.33 Billion	15.07%	0.27x	$5.07 Billion
Livzon Pharmaceutical Group Inc (000513)	$662.32 Million	12.10%	0.68x	$2.59 Billion
Wedge Industrial Co Ltd (000534)	$692.08 Million	2.78%	1.05x	$1.97 Billion
Yunnan Baiyao Group Co Ltd (000538)	$3.19 Billion	14.61%	0.55x	$13.23 Billion
Hainan Haiyao Co Ltd (000566)	$1.49 Billion	5.19%	0.85x	$1.11 Billion
Tus Pharmaceutical Group Co Ltd (000590)	$231.22 Million	-38.13%	1.23x	$302.41 Million
Northeast Pharmaceutical Group Co Ltd (000597)	$1.75 Billion	0.46%	2.42x	$956.43 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623)	$1.35 Billion	7.34%	0.44x	$3.16 Billion

About North China Pharmaceutical Co Ltd

SHG:600812 China Drug Manufacturers - Specialty & Generic

Market Cap

$1.20 Billion

CN¥8.17 Billion CNY

Market Cap Rank

#8140 Global

#1880 in China

Share Price

CN¥4.76

Change (1 day)

+0.00%

52-Week Range

CN¥4.20 - CN¥6.90

All Time High

CN¥18.60